Hookipa Pharma Inc has priced its initial public share offering on the US Nasdaq market at $14 per share to raise a gross $84 million, excluding any exercise of the underwriters’options. The proceeds will finance the company’s portfolio of immunotherapies targeting infectious diseases and cancers.
The European Parliament has given its backing to Horizon Europe, a multi-year research programme for the sciences with a proposed budget of €100 billion. The programme is scheduled to run from 2021 to 2027, succeeding Horizon 2020.
It will finance collaborative research projects across the sciences including healthcare and medicine research and development. Included in the programme is a European Innovation Council that will finance the work of entrepreneurs who are exploring new areas of science. This council has already been successfully operating as a pilot project.
The Belgian cell therapy company Promethera Biosciences SA has reported a positive safety profile and early efficacy signals from a Phase 2a study of its lead therapy for liver disease, HepaStem. HepaStem is an allogeneic therapy derived from the stem cells of healthy donors.
The stem cells are administered by infusion into the bloodstream of patients where they circulate until reaching the liver, settle and support regeneration.
Catalent Inc, a service provider for the biotech industry, is to pay $1.2 billion to acquire Paragon Bioservices Inc a company with expertise in adeno-associated virus (AAV) vectors for gene therapy. The New Jersey, US-based company said it expects the market for gene therapies to grow by 25% in the coming years.
Roche has confirmed plans to raise its dividend this year against a background of higher sales in the first quarter and regulatory approvals for three new indications for its cancer medicines in the US and drug approvals in cancer and haemophilia in the EU.
The Swiss company declared a dividend of CHF 8.70 per share for 2018.
The Dutch cell therapy company Kiadis Pharma NV has taken steps to strengthen its presence in the haematopoietic stem cell transplant sector with the agreed takeover of CytoSen Therapeutics Inc. The all-share transaction includes an upfront payment in stock as well as milestone payments contingent on the achievement of six clinical development and regulatory goals. CytoSen’s lead asset is a natural killer (NK) cell product designed to enable patients to receive a stem cell transplant from haploidentical donors. It is due to enter clinical development in 2020.
Gilead Sciences Inc and Novo Nordisk A/S of Denmark have decided to pool their resources to test a new combination therapy for the treatment of nonalcoholic steatohepatitis, a chronic and progressive liver disease characterised by the accumulation of fat and inflammation in the liver.
Alnylam Pharmaceuticals Inc has reported positive Phase 3 data for a trial of its ribonucleic acid interference (RNAi) drug, givosiran, in patients with acute hepatic porphyria (AHP). AHP refers to a family of rare, genetic diseases characterised by potentially life-threatening attacks and for some patients, chronic debilitating symptoms that negative affect their quality of life.
On the heels of a regulatory approval, Nanobiotix SA has raised €29.5 million in a private share placement to continue the clinical development of its radioenhancer products for the treatment of cancer. The placement was oversubscribed during an accelerated bookbuilding process. Both existing and new investors from the US and Europe supported the offering.
UK-based Destiny Pharma Plc is stepping up the pace of development for its lead antibacterial XF-73 with the start of a 200-patient Phase 2b study in April. The topical treatment is being investigated for the prevention of post-surgical staphylococcal infections including methicillin resistant Staphylococcus aureus (MRSA), a major public health threat. XF-73 is administered as a nasal gel where it has been shown to reduce the nasal carriage of the S. aureus bacteria.